A Prospective External Control Arm Study in Colorectal Cancer (COLOSSAL)

November 16, 2026 updated by: N-Power Medicine

NPM-009/COLOSSAL: A Prospective, Always-On Study to Generate Standardized External Control Arms Across Metastatic and MRD-Positive Early-Stage Colorectal Cancer

The goal of this observational, external control arm study is to make clinical trials faster, speed up developments of new therapies, and make trials more accessible to patients being treated at community oncology clinics.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

The purpose of this research is to better understand what treatments are given to patients with colorectal cancer, how the disease responds to treatments, and the generate reliable data that can be used as a comparison for new drugs in development.

Study Type

Observational

Enrollment (Estimated)

650

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with early stage or metastatic colorectal cancer

Description

Global Inclusion Criteria:

  1. 18 years at the time of initial colorectal cancer diagnosis
  2. Able to understand and provide informed consent
  3. Pathologically confirmed colorectal cancer per College of American Pathologists (CAP) guidelines
  4. Evidence of biomarker testing on tissue and/or blood

Early Stage CRC Inclusion Criteria

  1. Stage II-III disease per AJCC
  2. Positive ctDNA MRD results for specimen collected 4-8 weeks after curative intent surgery and before any adjuvant therapy
  3. Planning to start adjuvant therapy, or started it within the past 6 weeks prior to enrollment
  4. ECOG performance status of 0 or 1, documented on or within 21 days before the start of adjuvant therapy
  5. CT of the chest, abdomen, and pelvis (CT CAP) with contrast performed after surgery and up to 6 weeks prior to the start of adjuvant therapy

Metastatic CRC Inclusion Criteria

  1. Stage IV disease per AJCC or metastatic recurrence
  2. Planning to start adjuvant therapy, or started within the past 6 weeks prior to enrollment
  3. ECOG performance status of 0 or 1 documented on or within 21 days before the start of the new line of therapy
  4. CT of the chest, abdomen, and pelvis (CT-CAP) with contrast performed after surgery and up to 6 weeks prior to the start of a new line of therapy

Exclusion Criteria:

  1. Current enrollment in an interventional clinical trial
  2. Active therapy for a second, unrelated malignancy (excluding hormonal adjuvant therapy for breast cancer)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Early Stage MRD positive
Metastatic disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression Free Survival (PFS)
Time Frame: 5 years

Time from index date to the first evidence of progression assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on protocol imaging, or death, whichever occurs first. bicrPFS (months)=[(earliest date of BICR progression, death, or censoring-index date) +1] / 30.4375

5 years
Overall Response Rate (ORR)
Time Frame: 5 years

Proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) during a given line of therapy, from index until progression or the start of the next line, whichever occurs first, assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on-protocol imaging. Ranked CR ≥ PR ≥ stable disease (SD) ≥ progressive disease (PD) ≥ not evaluable (NE). CR and PR are confirmed by a subsequent assessment at least 28 days later. When the minimum interval is not met, BOR is determined by subsequent assessments. Participants lost to follow-up after an SD assessment that does not meet the minimum interval have a BOR of NE.

bicrORR (%) = (number of participants with BOR of CR or PR from index until earliest date of BICR progression or next line start ÷ number of participants in the response population) × 100

5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Next Treatment (TTNT)
Time Frame: 5 years

Time from index to the start of the next line of therapy or death, whichever occurs first. Participants who do not initiate a next line of therapy are censored at earliest of loss to followup and data cutoff.

TTNT (months) = [(earliest date of next line start, death, or censoring - index date) + 1] ÷ 30.4375.

5 years
Overall Survival (OS)
Time Frame: 5 years

Time from index to death from any cause. A missing date of death indicates the participant is alive at data cutoff, and the participant is censored at data cutoff.

OS (months) = [(earliest date of death or censoring - index date) + 1] ÷ 30.4375

5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2031

Study Completion (Estimated)

December 1, 2031

Study Registration Dates

First Submitted

October 28, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe